{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T10:06:02Z","timestamp":1764842762147,"version":"3.41.0"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Here we report clinical risk factors and event rates for the development of new non-melanoma skin cancer (NMSC) in a randomized, double-blind, placebo-controlled trial of the irreversible ornithine decarboxylase (ODC) inhibitor, difluromethylornithine (DFMO), over a 3\u20135-year follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>147 placebo patients (white; mean age 60.2 years; 60% male) were evaluated for event rates and association of initial skin biomarkers and baseline patient characteristics with the development of squamous cell (SCC) and basal cell (BCC) carcinomas.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Post-study evaluation (median follow-up 4.4 years) indicates the measures of prior NMSCs (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005\u2264\u20050.001), prior BCCs (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005\u2264\u20050.001), prior SCCs (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.011), prior tumor rate (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.002), hemoglobin (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.022), and gender (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.045) as significant predictors for new NMSC development. Similarly, all measures of prior BCCs and NMSCs (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001), prior tumor rate (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.014), and SCCs in the prior 2 years (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.047) were statistically significant predictors for new BCC development. Total prior NMSCs and those in the prior 5 years (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001), total prior SCCs and those in the prior 5 years (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001), total prior BCCs and those in the prior 5 years (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005\u2264\u20050.001), prior tumor rate (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.011) as well as age (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.008), hemoglobin (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.002), and gender (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.003) were statistically significant predictors of new SCC development. TPA-induced ODC activity at baseline showed no statistically significant association with the development of new NMSC (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.35), new BCCs (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.62), or new SCCs (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.25).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In the studied population, the history of and rate at which prior NMSCs occur are predictive and should be controlled for in future NMSC prevention trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cej.0000000000000829","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T09:00:34Z","timestamp":1688461234000},"page":"69-72","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Non-melanoma skin cancer event rates in a formalized clinical trial setting: considerations for clinical trial design"],"prefix":"10.1097","volume":"33","author":[{"given":"Taja","family":"Lozar","sequence":"first","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyungmann","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Havighurst","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary S.","family":"Wood","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill M.","family":"Kolesar","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard H.","family":"Bailey","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1940-6207.CAPR-09-0096","article-title":"A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of \u03b1-difluoromethylornithine in subjects with previous history of skin cancer.","volume":"3","author":"Bailey","year":"2010","journal-title":"Cancer Prev Res (Phila. Pa.)"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/1940-6207.CAPR-09-0248","article-title":"Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans.","volume":"3","author":"Elmets","year":"2010","journal-title":"Cancer Prev Res"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","article-title":"A systematic review of worldwide incidence of nonmelanoma skin cancer.","volume":"166","author":"Lomas","year":"2012","journal-title":"Br J Dermatol"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00420-019-01454-z","article-title":"Burden of non-melanoma skin cancer attributable to occupational sun exposure in Canada.","volume":"92","author":"Peters","year":"2019","journal-title":"Int Arch Occup Environ Health"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/bjc.2013.15","article-title":"Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.","volume":"108","author":"Raj","year":"2013","journal-title":"Br J Cancer"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:04:12Z","timestamp":1748361852000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000829","relation":{},"ISSN":["0959-8278"],"issn-type":[{"type":"print","value":"0959-8278"}],"subject":[],"published":{"date-parts":[[2023,7,3]]}}}